Skip to content

A Study to Compare the Efficacy and Safety of Ultrasound Guided Lead Implantation for Sacral Neuromodulation (SNM) in Subjects With Overactive Bladder (OAB) With X-Ray Guided Technique

A Study to Compare the Efficacy and Safety of Ultrasound Guided Lead Implantation for Sacral Neuromodulation (SNM) in Subjects With Overactive Bladder (OAB)With X-Ray Guided Technique

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02946723
Enrollment
30
Registered
2016-10-27
Start date
2017-02-28
Completion date
2019-02-28
Last updated
2016-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Overactive Bladder

Brief summary

Overactive bladder(OAB,Urgency) was determined by International Continence Society as Urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection (UTI) or other obvious pathology.The SNM treatment involves a two-stage surgical procedure performed under local anesthesia. The device include IPG (implantable programme generator) and lead. In the initial test phase, 1st stage, electrode is placed near the sacral nerve and requires a 2 weeks assessment. This allows your doctors and you to assess your initial response according to your voiding dairy and satisfaction. In 2nd stage, SNM procedure is implantation of the IPG. X ray guidance is harmful to both patients and doctors, while ultrasound guidance is real time visual guidance ,easy to operate by doctors and a radiation free option to challenge anatomy. Urologists are skilled in both ultrasound operations and anatomy basics and dedicating to developing better guidance technique in surgery. The study here compare the efficacy and safety of ultrasound versus X ray guidance technique in SNM.

Interventions

PROCEDUREultrasound

Lead implantation surgery for SNM using ultrasound guided technique

PROCEDUREX-ray

Lead implantation surgery for SNM using X-ray technique

Sponsors

Beijing Pins Medical Co., Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age \> 16 years; 2. Subjects suitable for SNM surgery; 3. Normal upper urinary tract function; 4. Bladder volume \> 100 mL; 5. Good compliance and able to complete the follow-up assessments.

Exclusion criteria

1. Psychiatric or neurologic disabilities on neurologic evaluation such as multiple sclerosis, spinal cord injury, epilepsy, Parkinson's disease, stroke; 2. Bladder lithiasis or tumor (cystoscopy or ultrasonography); 3. Stress urinary incontinence; 4. Bladder outlet obstruction; 5. Diuresis \> 3 liters per 24 hours; 6. Negative at the test period or previous treatment with SNM; 7. Pregnancy and plan to be pregnancy in 2 years.

Design outcomes

Primary

MeasureTime frameDescription
Successful rate6 months post -IPG implantationSuccessful rate is the percentage of patients who experienced a successful result (≥50% improvements in baseline symptoms ) as recorded in voiding dairies.

Secondary

MeasureTime frame
Adverse effectDuring operation, 2 weeks post-lead implantation, 3 and 6 months post -IPG implantation
Guidance technique performance timeFrom beginning operation until successful lead placement is completed
Times of X-ray radiationDuring operation
Overactive bladder symptom score (OABSS)pre-operation baseline, 2 weeks post-lead implantation, 3 and 6 months post -IPG implantation
Quality of Life (QoL) scorespre-operation baseline, 2 weeks post-lead implantation, 3 and 6 months post -IPG implantation

Contacts

Primary ContactFumin Jia, PhD
pins_medical@163.con010-59361265
Backup ContactLuming Li
010-60736388

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026